ERBB2 and breast cancer: Thus, growth of ErbB2 mammary tumours exhibited a non-significant reduction in constitutive BCL3 knockout mice compared to controls expressing normal levels of BCL3, with no significant changes in cyclinD1 or caspase3 levels within the mammary tumours.